Stem cell transplant is a life-saving treatment for many patients with hematologic malignancies and other life-threatening conditions.  Clinical outcomes and treatment options have greatly improved, but SCT continues to be a resource-intensive episode of care.  As the healthcare environment continues to move towards value-based purchasing and “pay-for-performance” reimbursement models, SCT and other high-cost, low utilization procedures will need to demonstrate the impact they have on the lives of their patient population.  Defining Quality and Value in Stem Cell Transplant has been developed as a forum for active discussion, deliberation and collaboration across traditional healthcare industry roles.  Health plan representatives, physicians, hospital administrators, healthcare purchasers and quality organization leaders will gather in cooperation to take the first step in identifying the future of quality and value in SCT.